Back to News
Market Impact: 0.15
Sensorion Secures ANSM Approval To Launch Phase I/II HearConnex Trial Of SENS-601 In France
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany FundamentalsAnalyst Insights
Sensorion SA received ANSM authorization to begin HearConnex, a Phase I/II clinical trial of SENS-601. The approval is a modest positive clinical/regulatory milestone for the company, but no efficacy results or timelines for outcomes were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Obama voices caution on AI, urges Democrats to tackle it, NYT says
- French AI boom exposes Europe’s funding gap as startups turn to U.S.
- Christine Lagarde: Interview with Ouest-France
- Amazon workers on food stamps have tripled despite its record revenue—and it’s just the latest evidence of the new economy of shrinking labor shares
- 5 big analyst AI moves: JPMorgan upgrades Meta, names KLA top chip equipment stock
- Is Lululemon Nearing Its Bottom?